London24NEWS

BUSINESS LIVE BofE base charge resolution; AstraZeneca flags China superb; Babcock lifts steerage

The Bank of England’s Monetary Policy Committee will reveal its decision on the direction of interest rates later today.

Markets are firmly pricing a 25 basis point base rate cut to 4.5 per cent and investors be looking closely at the bank’s commentary for clues as to the future of monetary policy.

The FTSE 100 is up 0.6 per cent in early trading. Among the companies with reports and trading updates today are AstraZeneca, Babcock, Compass and Watches of Switzerland Group. Read the Thursday 6 February Business Live blog below.

> If you are using our app or a third-party site click here to read Business Live

AstraZeneca set for solid growth despite China issues

Sheena Berry, healthcare analyst at Quilter Cheviot:

‘China has proven to be an overhang on the stock following the fraud investigations of several individuals, and questions remain on exactly what impact this might have on operations in China.

‘Sales declined 3% in the region, largely as a result of lower rates of seasonal respiratory viral infections and tightening hospital budgets. While the import tax allegation is certainly a headline generating blemish on the company, it appears manageable.

‘Looking ahead, 2025 guidance implies another year of solid growth is anticipated by management. AstraZeneca is guiding to high single digit total revenue growth in 2025, with earnings per share expected to increase to low double digits.

‘2025 is expected to be a catalyst rich year, and this should help provide investors with confidence in the group’s $80bn revenue ambition in 2030.’

MARKET REPORT: Mining shares boosted as gold hits record high

Defence group Babcock lifts guidance

Defence group Babcock has hiked revenue expectations for the year on the back of strength in its nuclear and marine segments.

The group expects to post around £4.9billion pounds in sales for the year, compared to analyst forecasts of approximately £4.67billion.

Boss David Lockwood said: ‘Today’s announcement demonstrates that successful execution of our strategy is continuing to deliver value for all our stakeholders.

‘Our engineering skills and know-how are in ever greater demand and with significant opportunities before us, I look forward to further profitable growth.’

AstraZeneca flags China fine

AstraZeneca faces a potential fine over unpaid taxes in China, the drugmaker told investors this morning.

The FTSE 100 firm has received a notice in China over unpaid taxes related to the import of two cancer therapies.

It comes at AstraZeneca continues to gauge the impact of probes into certain executives and activities in the key market.

Last December, AstraZeneca named Iskra Reic as its new international executive vice president, who took over from Leon Wang in its efforts to stabilise its operations in China, after Wang was detained by Chinese authorities in October.

A fine of between one and five times the unpaid tax amount of $0.9million may be levied if the company is found liable.

It came as the group reported fourth-quarter earnings and forecast 2025 sales above analyst expectations.

Bank of England set to cut base rate

The Bank of England’s Monetary Policy Committee will reveal its decision on the direction of interest rates later today.

Markets are firmly pricing a 25 basis point base rate cut to 4.5 per cent and investors be looking closely at the bank’s commentary for clues as to the future of monetary policy.

Peder Beck-Friis, economist at Pimco, said:.

‘Looking ahead, we see room for deeper cuts than what financial markets expect. Trade uncertainty is rising, labour demand is falling, fiscal policy is tight, and the policy rate is well above our neutral estimate of 2 to 3 per cent.

‘While inflation will likely rise in the coming quarters, the main driver—the national insurance hike—is a one-time tax shock that central banks typically look through. If wage growth falls and the labour market weakens, we expect the Monetary Policy Committee to look through any short-term price pressures and instead focus on the medium-term outlook.

‘Recent weeks have seen a significant decline in gilt yields. We think gilts remain attractive at their current levels.’